217 related articles for article (PubMed ID: 27858183)
1. Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.
Hori H; Kudoh T; Nishimura S; Oda M; Yoshida M; Hara J; Tawa A; Usami I; Tanizawa A; Yumura-Yagi K; Kato K; Kobayashi R; Komada Y; Matsuo K; Horibe K;
Int J Clin Oncol; 2017 Apr; 22(2):387-396. PubMed ID: 27858183
[TBL] [Abstract][Full Text] [Related]
2. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
[TBL] [Abstract][Full Text] [Related]
3. Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia.
Shimomura Y; Baba R; Watanabe A; Horikoshi Y; Asami K; Hyakuna N; Iwai A; Matsushita T; Yamaji K; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2011 Sep; 57(3):461-6. PubMed ID: 21298773
[TBL] [Abstract][Full Text] [Related]
4. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
5. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
Messinger Y; Uckun FM
Leuk Lymphoma; 1999 Aug; 34(5-6):415-32. PubMed ID: 10492065
[TBL] [Abstract][Full Text] [Related]
6. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
Rammeloo LA; Postma A; Sobotka-Plojhar MA; Bink-Boelkens MT; Berg A; Veerman AJ; Kamps WA
Med Pediatr Oncol; 2000 Jul; 35(1):13-9. PubMed ID: 10881002
[TBL] [Abstract][Full Text] [Related]
7. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
10. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
11. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
12. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
[TBL] [Abstract][Full Text] [Related]
13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
14. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
16. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
18. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
[TBL] [Abstract][Full Text] [Related]
19. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
20. Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F; Zimmermann M; Jorch N; Pekrun A; Borkhardt A; Imschweiler T; Christiansen H; Faber J; Feuchtinger T; Schmid I; Beron G; Horstmann MA; Escherich G
Leuk Lymphoma; 2019 Jan; 60(1):60-68. PubMed ID: 29966458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
